340 related articles for article (PubMed ID: 25843781)
1. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.
Corkery JM; Loi B; Claridge H; Goodair C; Corazza O; Elliott S; Schifano F
Neurosci Biobehav Rev; 2015 Jun; 53():52-78. PubMed ID: 25843781
[TBL] [Abstract][Full Text] [Related]
2. Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom Communities Associated with GHB and Precursors.
Corkery JM; Loi B; Claridge H; Goodair C; Schifano F
Curr Drug Metab; 2018; 19(13):1086-1099. PubMed ID: 29119924
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons.
Goodwin AK; Brown PR; Jansen EE; Jakobs C; Gibson KM; Weerts EM
Psychopharmacology (Berl); 2009 Jun; 204(3):465-76. PubMed ID: 19198808
[TBL] [Abstract][Full Text] [Related]
4. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
[TBL] [Abstract][Full Text] [Related]
5. GHB, GBL and 1,4-BD addiction.
Brunt TM; van Amsterdam JG; van den Brink W
Curr Pharm Des; 2014; 20(25):4076-85. PubMed ID: 24001290
[TBL] [Abstract][Full Text] [Related]
6. [GHB--dangerous, addictive and uncontrollable "party drug"].
Persson SA; Eriksson A; Hallgren N; Eklund A; Berkowicz A; Druid H
Lakartidningen; 2001 Sep; 98(38):4026-31, 4033-5. PubMed ID: 11602959
[TBL] [Abstract][Full Text] [Related]
7. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD).
Wood DM; Warren-Gash C; Ashraf T; Greene SL; Shather Z; Trivedy C; Clarke S; Ramsey J; Holt DW; Dargan PI
QJM; 2008 Jan; 101(1):23-9. PubMed ID: 18203723
[TBL] [Abstract][Full Text] [Related]
8. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
Wood DM; Brailsford AD; Dargan PI
Drug Test Anal; 2011; 3(7-8):417-25. PubMed ID: 21548140
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of equimolar doses of gamma-hydroxybutyrate (GHB), 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL) on catalepsy after acute and chronic administration.
Towiwat P; Phattanarudee S; Maher TJ
Food Chem Toxicol; 2013 Jan; 51():337-42. PubMed ID: 23104245
[TBL] [Abstract][Full Text] [Related]
10. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
[TBL] [Abstract][Full Text] [Related]
11. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate.
Palmer RB
Toxicol Rev; 2004; 23(1):21-31. PubMed ID: 15298490
[TBL] [Abstract][Full Text] [Related]
12. [Current knowledge on gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL) and 1 ,4-butanediol (1,4-BD)].
Dematteis M; Pennel L; Mallaret M
Rev Prat; 2012 May; 62(5):669-72. PubMed ID: 22730800
[TBL] [Abstract][Full Text] [Related]
13. Gamma-Hydroxybutyrate (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion.
Sadasivan S; Maher TJ; Quang LS
Ann N Y Acad Sci; 2006 Aug; 1074():537-44. PubMed ID: 17105951
[TBL] [Abstract][Full Text] [Related]
14. Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats.
Carter LP; Koek W; France CP
Eur J Neurosci; 2006 Nov; 24(9):2595-600. PubMed ID: 17100847
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
Wojtowicz JM; Yarema MC; Wax PM
CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.
Kamal RM; van Noorden MS; Wannet W; Beurmanjer H; Dijkstra BA; Schellekens A
CNS Drugs; 2017 Jan; 31(1):51-64. PubMed ID: 28004314
[TBL] [Abstract][Full Text] [Related]
17. Inpatient management of GHB/GBL withdrawal.
Delic M
Psychiatr Danub; 2019 Sep; 31(Suppl 3):354-356. PubMed ID: 31488752
[TBL] [Abstract][Full Text] [Related]
18. [GHB, GBL and butanediol poisonings--a serious problem in Western Sweden].
Knudsen K; Greter J; Verdicchio M; Cederquist T
Lakartidningen; 2005 Nov 7-13; 102(45):3294-6, 3299. PubMed ID: 16342543
[TBL] [Abstract][Full Text] [Related]
19. Consequences of 1,4-Butanediol Misuse: A Review.
Skryabin V; Shevtsova Y; Novoselova EA
Psychopharmacol Bull; 2023 Dec; 53(4):48-53. PubMed ID: 38076667
[TBL] [Abstract][Full Text] [Related]
20. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
McDaniel CH; Miotto KA
J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
